Coherus BioSciences (CHRS) Competitors

Cogent Biosciences (NASDAQ:COGT) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.

Which has more risk and volatility, COGT or CHRS?

Cogent Biosciences has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Does the media prefer COGT or CHRS?

In the previous week, Cogent Biosciences had 5 more articles in the media than Coherus BioSciences. MarketBeat recorded 13 mentions for Cogent Biosciences and 8 mentions for Coherus BioSciences. Cogent Biosciences' average media sentiment score of 0.79 beat Coherus BioSciences' score of 0.51 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus BioSciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of COGT or CHRS?

72.8% of Coherus BioSciences shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by company insiders. Comparatively, 7.6% of Coherus BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has higher earnings & valuation, COGT or CHRS?

Cogent Biosciences has higher earnings, but lower revenue than Coherus BioSciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$192.41M	-$1.94	-3.03
Coherus BioSciences	$266.96M	0.48	-$237.89M	$0.19	5.79

Is COGT or CHRS more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-112.55%	-60.44%
Coherus BioSciences	-0.15%	N/A	-24.44%

Do analysts rate COGT or CHRS?

Cogent Biosciences presently has a consensus target price of $14.43, indicating a potential upside of 145.80%. Coherus BioSciences has a consensus target price of $5.26, indicating a potential upside of 378.41%. Given Coherus BioSciences' higher possible upside, analysts clearly believe Coherus BioSciences is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Coherus BioSciences	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the MarketBeat Community prefer COGT or CHRS?

Coherus BioSciences received 160 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.22% of users gave Cogent Biosciences an outperform vote while only 65.12% of users gave Coherus BioSciences an outperform vote.

Company	Underperform	Outperform
Cogent Biosciences	Outperform Votes 290 70.22%	Underperform Votes 123 29.78%
Coherus BioSciences	Outperform Votes 450 65.12%	Underperform Votes 241 34.88%

Summary

Cogent Biosciences beats Coherus BioSciences on 9 of the 17 factors compared between the two stocks.